HDAC2 and breast cancer: These findings are consistent with those of Müller et al. [30], who showed that the expression of class 1 HDAC isoenzymes is deregulated in breast cancer samples, and that varying expression levels of HDAC1, HDAC2 and HDAC3 correlated with clinicopathological parameters.